References

transmed

Трансляционная медицина

Translational Medicine

2311-44952410-5155

Almazov National Medical Research Centre, Saint Petersburg, Russia

10.18705/2311-4495-2014-0-1-13-22

transmed-3

Research Article

РЕДАКЦИОННАЯ СТАТЬЯ

ТРАНСЛЯЦИОННЫЕ ИССЛЕДОВАНИЯ КАК МОДЕЛЬ РАЗВИТИЯ СОВРЕМЕННОЙ МЕДИЦИНСКОЙ НАУК

TRANSLATIONAL RESEARCH AS A MODEL OF PROGRESS IN CURRENT MEDICAL SCIENCE

Шляхто

Евгений Владимирович

Shlyakhto

Eugene V.

e.shlyakhto@almazovcentre.ru

ФГБУ «Федеральный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России; ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияFederal Almazov Medical Research Centre; First Pavlov State Medical University of St. PetersburgRussian Federation

2014

23122016

01518

2016

Шляхто Е.В.

Shlyakhto E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://transmed.almazovcentre.ru/jour/article/view/3

Трансляционная медицина - новое научное направление, призванное сократить и, в идеале, ликвидировать существующий разрыв между научными изобретениями и повседневной медицинской практикой. В обзоре рассматривается история становления концепции трансляционных исследований в медицине, а также обобщается имеющийся опыт проведения трансляционных медицинских разработок в США и Европе. Описаны основные фазы и модели трансляционного процесса, трансляционные барьеры и пути их преодоления. Отдельное внимание уделено оценке трансляционного потенциала новых технологий, которая является залогом их эффективного внедрения в практику. Решение проблемы переноса достижений фундаментальной науки в клинику требует комплексного подхода, который должен базироваться на трех основополагающих принципах: высоком качестве проводимых научных исследований, безупречном менеджменте трансляционных проектов и налаживании продуктивного диалога между представителями различных профессиональных сообществ.

Translational medicine is a new concept which aims reduction of the distance between basic science discoveries and routine medical practice. This review focuses on the history of the concept of translational research in medicine and summarizes the current state of translational biomedical studies in USA and Europe. In addition, the phases and models of translational process are described, as well as the major translational barriers. Special attention is paid to the estimation of translation potential of new technologies which guarantees the success of translation. The problem of improved translation of new knowledge to clinical realm requires complex approach, including three basic principles: highest possible quality of research, perfect management of translational projects, and setting up an efficient dialogue between the representatives of different professional teams.

трансляционная медицинатрансляционные исследованиятрансляционные барьерыдоклинические исследованияразработка лекарственных препаратовлечебные и диагностические технологиибиомедицинские инновацииtranslational medicinetranslational researchtranslational barrierspreclinical studiesdrug developmenttherapeutic and diagnostic techniquesbiomedical innovation

References1

DiMasi J.A., Grabowski H.G. Economics of new oncology drug development // J. Clin. Oncol. - 2007. - Vol. 25, № 2. - P. 209-216.

Contopoulos-Ioannidis D.G., Ntzani E., Ioannidis J.P. Translation of highly promising basic science research into clinical applications // Am. J. Med. - 2003. - Vol. 114, № 6. - P. 477-484.

Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates? // Nat. Rev. Drug Discov. - 2004. - Vol. 3, № 8. - P. 711-715.

Marincola F.M. Translational medicine: A two-way road // J. Transl. Med. - 2003. - Vol. 1, № 1. - P. 1.

Zerhouni E.A. Translational and clinical science-time for a new vision // N. Engl. J. Med. -2005. - Vol. 353, № 15. - P. 1621-1623.

Choi D.W. Bench to bedside: the glutamate connection // Science. - 1992. - Vol. 258, № 5080. - P. 241-243.

Editor. Phagocytes and the «bench-bedside interface» // N. Eng. J. Med. - 1968. - Vol. 278. - P. 1014-1016.

Rubio D.M., Schoenbaum E.E., Lee L.S. et al. Defining translational research: Implications for training // Academic Med. - 2010. - Vol. 85. - P. 470-475.

Brander C., Ferrone S., Marincola F.M. Rewarding patient-directed research: Excellence in Translational Medicine Award // J. Transl. Med. - 2006. - Vol. 4. - P. 19.

Интернет-ресурс, URL: http://www.gloucestershire.police.uk/counterterrorism/CTSAs%20Advice/item3983.html

Woolf S.H. The meaning of translational research and why it matters // JAMA: The Journal of the American Medical Association. - 2008. - Vol. 299. - P. 211-213.

Sung N.S., Crowley W.F.J., Genel M., Salber P., Sandy L., Sherwood L.M., et al. Central challenges facing the national clinical research enterprise // JAMA. - 2003. - Vol. 289, № 10. - P. 1278-1287.

Westfall J.M., Mold J., Fagnan L. Practice-based research - «Blue Highways» on the NIH roadmap // JAMA. - 2007. - Vol. 297, № 4. - P. 403-406.

Tageja N. Bridging the translation gap - new hopes, new challenges // Fundam. Clin. Pharmacol. - 2011. - Vol. 25, № 2. - P. 163-171.

Morris Z.S., Wooding S., Grant J. The answer is 17 years, what is the question: understanding time lags in translational research // J.R. Soc. Med. - 2011. - Vol. 104, № 12. - P. 510-520.

Decullier E., Lheritier V., Chapuis F. Fate of biomedical research protocols and publication bias in France: retrospective cohort study // BMJ. - 2005. - Vol. 331. - P. 19.

Grant J., Cottrel L.R., Cluzeau F., Fawcett G. Evaluating «payback» on biomedical research from papers cited in clinical guidelines: applied bibliometric study // BMJ. - 2000. - Vol. 320. - P. 1107-1111.

Sternitzke C. Knowledge sources, patent protection, and commercialization of pharmaceutical innovations // Res. Policy. - 2010. - Vol. 39. - P. 810-821.

Ioannidis J. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials // JAMA. - 1998. - Vol. 279. - P. 281.

Wratschko K. Empirical Setting: The pharmaceutical industry. Strategic Orientation and Alliance Portfolio Configuration. New York, NY: Springer, 2009.

Balas E., Boren S. Managing clinical knowledge for health care improvement / van Bemmel J.H., McCray A.T. eds. Yearbook of Medical Informatics. - Stuttgart: Schattauer Verlagsgesellschaft mbH, 2000. - P. 65-70.

Trochim W., Kane C., Graham M.J., Pincus H.A. Evaluating translational research: a process marker model // Clin. Transl. Sci. - 2011. - Vol. 4, № 3. - P. 153-162.

Prabhakar S. Translational research challenges: finding the right animal models // J. Investig. Med. - 2012. - Vol. 60, № 8. - P. 1141-1146.

Storer R.D., Sistare F.D., Reddy M.V., DeGeorge J.J. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development // Toxicol. Pathol. - 2010. - Vol. 38, № 1. - P. 51-61.

Galagudza M., Blokhin I.O., Shmonin A.A., Mischenko K.A. Reduction of myocardial ischemia-reperfusion injury with pre- and postconditioning: molecular mechanisms and therapeutic targets // Cardiovasc. Hematol. Disord. Drug Targ. - 2008. - Vol. 8, № 1. - P. 47-65.

Шляхто Е.В., Нифонтов Е.М., Галагудза М.М. Пре- и посткондиционирование как способы кардиоцитопротекции: патофизиологические и клинические аспекты // Сердечная недостаточность. - 2008. - Т. 9, № 1. - С. 4-10.

Miura T., Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy // Basic Res. Cardiol. - 2008. - V. 103, № 6. - P. 501-513.

Ludman A.J., Yellon D.M., Hausenloy D.J. Cardiac preconditioning for ischaemia: lost in translation // Dis. Model. Mech. - 2010. - Vol. 3, № 1-2. - P. 35-38.

Cohen M.V., Downey J.M. Is it time to translate ischemic preconditioning’s mechanism of cardioprotection into clinical practice? // J. Cardiovasc. Pharmacol. Ther. - 2011. - Vol. 16, № 3-4. - P. 273-280.

Lefer D.J., Bolli R. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation // J. Cardiovasc. Pharmacol. Ther. - 2011. - Vol. 16, № 3. - P. 332-339.

Pitarys C.J., Virmani R., Vildibill H.D. et al. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period // Circulation. - 1991. - Vol. 83, № 1. - P. 237-247.

Velasco C.E., Turner M., Cobb M.A. et al. Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine // Am. Heart J. - 1991. - Vol. 122, № 6. - P. 1561-1570.

Norton E. D., Jackson E. K., Turner M. B. et al. The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury // Am. Heart J. - 1992. - Vol. 123, № 2. - P. 332-338.

Vander Heide R.S., Reimer K.A. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs // Cardiovasc. Res. - 1996. - Vol. 31, № 5. - P. 711-718.

Goto M., Miura T., Iliodoromitis E.K. et al. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species // Cardiovasc. Res. -1991. - Vol. 25, № 11. - P. 943-949.

Budde J.M., Velez D.A., Zhao Z.Q. et al. Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury duringh of reperfusion // Cardiovasc. Res. - 2000. - Vol. 47, № 2. - P. 294-305.

Mahaffey K.W., Puma J.A., Barbagelata N.A. et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial // J. Am. Coll. Cardiol. - 1999. - Vol. 34, № 6. - P. 1711-1720.

Ross A.M., Gibbons R.J., Stone G.W. et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) // J. Am. Coll. Cardiol. - 2005. - Vol. 45, № 11. - P. 1775-1780.

Piot C., Croisille P., Staat P. et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction // N. Engl. J. Med. - 2008. - Vol. 359, № 5. - P. 473-481.

Hausenloy D.J., Baxter G., Bell R. et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations // Basic Res. Cardiol. - 2010. - Vol. 105, № 6. - P. 677-686.

Шляхто Е.В., Баранцевич Е.Р., Щербак Н.С., Галагудза М.М. Молекулярные механизмы формирования ишемической толерантности головного мозга. Часть 1 // Вестник Российской академии медицинских наук. - 2012. - № 6. - С. 42-50.

Шляхто Е.В., Баранцевич Е.Р., Щербак Н.С., Галагудза М.М. Молекулярные механизмы формирования ишемической толерантности головного мозга. Часть 2 // Вестник Российской академии медицинских наук. - 2012. - № 7. - С. 20-29.

Recommendations for standards regarding preclinical neuroprotective and restorative drug development // Stroke. - 1999. - Vol. 30. - P. 2752-2758.

Fisher M., Feuerstein G., Howells D.W. et al. STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations // Stroke. - 2009. - Vol. 40. - P. 2244-2250.

O’Collins V.E., Macleod M.R., Donnan G.A., Horky L.L., van der Worp B.H., Howells D.W. 1,026 experimental treatments in acute stroke // Ann. Neurol. - 2006. - Vol. 59. - P. 467-477.

Lapchak P.A., Zhang J.H., Noble-Haeusslein L.J. RIGOR guidelines: escalating STAIR and STEPS for effective translational research // Transl. Stroke Res. - 2013. - Vol. 4, № 3. - P. 279-285.

Schneider G. Virtual screening: An endless staircase? // Nat. Rev. Drug Discov. - 2010. - Vol. 9. - P. 273-276.

Inoue H., Yamanaka S., The use of induced pluripotent stem cells in drug development // Clin. Pharmacol. Ther. - 2011. - Vol. 89. - P. 655.

Wehling M. Drug development in the light of translational science: shine or shade? // Drug Discov. Today. - 2011. - Vol. 16. № 23-24. - P. 1076-1083.

Nicholls S.J., Tuzcu E.M., Brennan D.M., Tardif J.C., Nissen S.E. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) // Circulation. - 2008. - Vol. 118, № 24. - P. 2506-2514.

The authors declare that there are no conflicts of interest present.